Contract Lifecycle Management (CLM) is often caught in cross-functional turf wars. Consequently, many find that the system in place is not the hoped-for “silver bullet,” especially as unmet requirements surface across the organization. Moreover, the benefits documented in the CLM business case may always seem just beyond reach, especially as phased roll-outs stall amidst frustration and disappointment that what was pitched by the vendor turned out to be more difficult to actualize than it seemed.
The draft guidelines for applying US antitrust laws to merger investigations depart from prior guidance and seek to roll back decades of legal precedent on merger enforcement. In this Client Alert, Latham attorneys highlight the key takeaways and the most significant developments in the new guidelines for companies considering strategic M&A opportunities.
In the July issue of the ACC Observer, David Cambria shared his unique and broad perspective on legal operations' current trajectory. This column focuses on Cambria's career experience, which makes his insights worth contemplating.
Despite improvements in cybersecurity-related disclosures, the SEC observed inconsistency in reporting practices. The objective of the new rules is to achieve uniform, comparable, and decision-useful disclosures that empower investors to make well-informed evaluations of a company’s cybersecurity posture. This resource from Womble Bond Dickinson delves into the final rules that enhance cybersecurity disclosure.
This article from Womble Bond Dickinson assesses some of the drivers of supply chain disruption in the U.S. and Europe and considers what businesses can do to mitigate the risks. These issues are likely to impact all sectors, however, they have particularly impacted the construction industry in recent years.
An Interview with David Cambria
Legal Ops’ OG Maverick has an eye on the bright future of the industry
Artificial Intelligence (AI) has become an even hotter topic since the introduction of generative AI tools like ChatGPT, a chatbot developed by OpenAI, as well as tools like Copilot and OpenAI Codex, which use generative AI to write computer code. This resource from Womble Bond Dickinson discusses the best practices in using Artificial Intelligence to generate code.
This resource from Womble Bond Dickinson discusses how Generative Artificial Intelligence can impact case law.
This blog focuses on U.S. Food and Drug Administration (FDA) published framework to guide regulatory decision-making on the use of digital health technologies (DHT) in clinical drug trials. DHTs include a wide array of technologies, including software applications that run on a phone, wearables, and environmental sensors, among others. As DHT becomes more sophisticated, the technologies have the potential to play an even larger role in health care, including clinical research.
This blog explores the U.S. Food & Drug Administration (FDA) two final guidance documents to assist with transitioning medical devices: (i) that were subject to certain enforcement policies issued during the COVID-19 Public Health Emergency (PHE), and (ii) that were issued emergency use authorizations (EUAs). These guidance documents finalize the corresponding draft guidance documents that were issued on December 23, 2021.